Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) CFO Patrik Jeanmonod sold 3,500 shares of the company’s stock in a transaction that occurred on Tuesday, January 24th. The stock was sold at an average price of $11.05, for a total value of $38,675.00. Following the sale, the chief financial officer now directly owns 76,132 shares in the company, valued at $841,258.60. The sale was disclosed in a filing with the SEC, which is available through this link.
Patrik Jeanmonod also recently made the following trade(s):
- On Tuesday, December 27th, Patrik Jeanmonod sold 3,500 shares of Cytek Biosciences stock. The shares were sold at an average price of $9.77, for a total transaction of $34,195.00.
- On Friday, November 25th, Patrik Jeanmonod sold 3,500 shares of Cytek Biosciences stock. The stock was sold at an average price of $14.30, for a total transaction of $50,050.00.
Cytek Biosciences Price Performance
Shares of Cytek Biosciences stock traded up $0.29 during trading on Wednesday, hitting $11.53. The stock had a trading volume of 645,055 shares, compared to its average volume of 781,979. Cytek Biosciences, Inc. has a 12 month low of $7.38 and a 12 month high of $16.05. The firm’s fifty day simple moving average is $11.62 and its 200-day simple moving average is $12.99.
Hedge Funds Weigh In On Cytek Biosciences
Several hedge funds have recently bought and sold shares of the business. Royal Bank of Canada lifted its position in shares of Cytek Biosciences by 222.0% during the third quarter. Royal Bank of Canada now owns 2,074 shares of the company’s stock worth $30,000 after purchasing an additional 1,430 shares during the last quarter. Metropolitan Life Insurance Co NY grew its stake in Cytek Biosciences by 31.5% in the 1st quarter. Metropolitan Life Insurance Co NY now owns 6,415 shares of the company’s stock worth $69,000 after acquiring an additional 1,536 shares in the last quarter. Credit Suisse AG increased its position in shares of Cytek Biosciences by 3.5% during the third quarter. Credit Suisse AG now owns 47,115 shares of the company’s stock worth $694,000 after acquiring an additional 1,604 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of Cytek Biosciences by 54.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 5,077 shares of the company’s stock valued at $74,000 after acquiring an additional 1,789 shares in the last quarter. Finally, FMR LLC boosted its holdings in shares of Cytek Biosciences by 0.5% in the second quarter. FMR LLC now owns 520,845 shares of the company’s stock valued at $5,589,000 after purchasing an additional 2,616 shares during the period. Institutional investors own 49.48% of the company’s stock.
Analysts Set New Price Targets
Separately, Piper Sandler lifted their price target on Cytek Biosciences from $16.00 to $18.00 in a research report on Monday, November 14th.
About Cytek Biosciences
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.